Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer

Breast Cancer

Volumn 24, Issue 1, 2017, Pages 147-151

  Yoshinami, Tetsuhiro ^a   Yagi, Toshinari ^a   Okuno, Jun ^a   Kittaka, Nobuyoshi ^a   Ishitobi, Makoto ^a   Sugimoto, Naotoshi ^a   Nakayama, Takahiro ^a   Tamaki, Yasuhiro ^a   Imamura, Fumio ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Bevacizumab with paclitaxel; Metastatic breast cancer; Re induction therapy

Indexed keywords

BEVACIZUMAB; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; INFECTIOUS PNEUMONIA; MEDICAL RECORD REVIEW; METASTATIC BREAST CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEINURIA; RE-INDUCTION THERAPY; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; STOMATITIS; THROMBOCYTOPENIA; TOXIC HEPATITIS; TUMOR BLEEDING; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; INDUCTION CHEMOTHERAPY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; FATIGUE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84961674886     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-016-0686-3     Document Type: Article

References (12)

1. Hurwitz H, Fehrenbacher L, Novtony W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
2. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel carboplatin alone or with bevacizumab for non small-cell lung cancer. N Engl J Med. 2006;355:2542–50.
4. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.
5. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.
6. Hershman DL, Lacchetti C, Dworkin RH, Smith EML, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology and Clinical Practice. J Clin Oncol. 2014;32:1941–67.
7. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novonty WF, et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30:117–24.
8. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47.
9. von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1269–78.
10. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer. J Clin Oncol. 2011;29:4286–93.
11. Yoshinami T, et al. SABCS 2013 Abst#OT3-1-01.
12. Saji S, et al. ASCO 2014 Abst#TPS657.